Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
Dyadic International, Inc. (NASDAQ: DYAI) will report its financial results for the first quarter of 2023 on May 10, 2023, at 5:00 p.m. ET. This follows the company's focus on innovative microbial platforms aimed at increasing global protein bioproduction and improving access to biopharmaceutical products for human and animal health. Dyadic utilizes advanced technology based on the fungus Thermothelomyces heterothallica, enhancing the development and manufacturing of biologics. Their lead asset, DYAI-100, is a COVID-19 vaccine candidate, showcasing the company's commitment to addressing unmet clinical needs. A webcast of the conference call will be available post-event for investors and stakeholders.
- Focus on innovative microbial platforms for global protein bioproduction.
- Lead asset DYAI-100 is a COVID-19 vaccine candidate.
- Webcast available within 24 hours post-conference for investor engagement.
- None.
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.
Conference Call Information
Date: Wednesday, May 10, 2023
Time: 5:00 p.m. Eastern Time
Dial-in numbers: Toll Free: 877-407-0784; International +1-201-689-8560
Conference ID: 13734863
Webcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1588259&tp_key=9ecbb63ff2. An archive of the webcast will be available within 24 hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.dyadic.com. To access the replay of the webcast, please follow the webcast link above.
If you have any questions that you would like to ask management during the Q&A session, please email hzosiak@dyadic.com prior to the conference call.
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products.
To learn more about Dyadic and our commitment to helping bring vaccines and other biologic products to market faster, in greater volumes and at lower cost, please visit https://www.dyadic.com.
Safe Harbor Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research projects and third-party collaborations, as well as the availability of necessary funding. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company’s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com.
Contact:
Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: ir@dyadic.com
FAQ
What is the date of Dyadic International's Q1 2023 financial results report?
What time will Dyadic International's conference call be held?
How can I access the webcast of Dyadic International's conference call?
What is Dyadic International's lead product?
